The company is just so much better known its medical countermeasures against biological threats like anthrax than for its cancer work, and that’s a problem.
We’ve been covering news of the GlucoTrack non-invasive glucometer for almost a decade now, and finally Integrity Applications, the company behind the device, is moving toward clinical trials potential regulatory approval in the U.S. The Israeli firm already received the CE mark in Europe for the GlucoTrack model DF-F two years ago, and the same device is in the pre-submission documents filed with the FDA.
The GlucoTrack uses an ear lobe clip-on similar to pulse oximeters to spot glucose levels through the skin. The sensor uses three different technologies to estimate blood glucose and sends its readings to a smartphone-like device that displays the numbers and keeps track of previous tests.
With the financial aid of a biotechnology executive whose daughter may need a lung transplant, U.S. researchers have been shattering records in xenotransplantation, or between-species organ transplants.
The researchers say they have kept a pig heart alive in a baboon for 945 days and also reported the longest-ever kidney swap between these species, lasting 136 days. The experiments used organs from pigs “humanized” with the addition of as many as five human genes, a strategy designed to stop organ rejection.
Betamore and Plank Industries, Under Armour CEO Kevin Plank’s private investment arm, are teaming up to showcase Baltimore startups in a new entrepreneurship event.
The Oct. 1 event, called Beta City, is intended to highlight promising Baltimore startups, connect entrepreneurs to venture capitalists and showcase Baltimore as an emerging startup hub. The day will include a pitch session, a VIP event at Plank Industries’ new innovation center and networking opportunities.
Mere months after a major venture capital fundraise, Rockville-based biotech RegenxBio Inc. says it’s ready to go public. UPCOMING EVENTS AUGUST 18, 2015 , 11:45AM Washington Business Journal: Lead Generation Seminar
In an initial regulatory filing Monday with the Securities and Exchange Commission, the company said it would trade on the Nasdaq exchange under the ticker symbol RGNX. It has yet to say how much it plans to raise and set either a price for the stock or date for the initial public offering. Morgan Stanley & Co. LLC (NYSE: MS), BofA Merrill Lynch, Piper Jaffray and Chardan Capital Markets LLC will manage the IPO.
WuXi PharmaTech (Cayman) Inc. (“WuXi” or the “Company”) (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New WuXi Life Science Limited (“Parent”) and WuXi Merger Limited (“Merger Sub”), a wholly owned subsidiary of Parent.
Healthcare, agriculture, and manufacturing remain the bread and butter of the private sector in Madison, WI, and the surrounding region, but healthcare IT has arguably become the area’s most buzz-worthy industry.
Today, Xconomy is adding to the conversation about healthtech’s ascent in the local economy. A new analysis of data gathered by the Madison Region Economic Partnership (MadREP) found that there are at least 43 healthtech companies in Dane County employing around 10,000 people. (The list may not be comprehensive, so e-mail us if we missed any companies.)
Scientists throughout are celebrating the scoop that the arena’s first vaccine towards malaria has been authorized by way of the .
The vaccine, named Mosquirix, used to be given the fairway gentle on Friday after , detailed in 230,000 pages of knowledge. It now signifies that the vaccine might be tested via the Global Well being Organisation and, if authorized, may well be administered to youngsters throughout Africa inside of the following few years.
Inovio Pharmaceuticals has begun collaboration and sold the exclusive rights to an HPV types 16 and 18 vaccine to MedImmune, the biologics research and development arm of AstraZeneca, for $700 million, according to a press release.
“[The] collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific, T-cell responses,” David Berman, MD, PhD, senior vice president and head of MedImmune’s oncology medicine development unit, said in the release.
The Maryland region is one of the richest sources of health care knowledge and research innovation in the world. Here you can find more than 800 life sciences companies, 70 federal labs, regulatory agencies such as the U.S. Food and Drug Administration (FDA), and elite academic, medical and research institutions. Most of these resources are unique to our area and cannot be replicated anywhere else in the U.S.